Connect with us

News

Delivery system enables administration of psychedelics without side effects

Published

on

Delivery system enables administration of psychedelics without side effects

Psycheceutical has been granted exclusive license of two major patents that will psychedelic compounds to be administered without any side effects.

Psycheceutical‘s patented delivery systems will enable psychedelics such as psilocybin, ibogaine and ketamine to be administered without side effects and toxicity by bypassing the stomach and the liver.

The delivery systems will enable the administration of psychedelic compounds without passing through the digestive tract, which will improve uptake and minimise harmful side effects, and will also eliminate the hallucinogenic effect of the compounds.

The delivery systems  

The first system, the Janus particle solution, which was established following groundbreaking research conducted at the University of Michigan by Professor Dr Anish Tuteja, uses layered nanoparticles that target specific cells and deliver multiple medicines at different times and rates.

Dr Tuteja, who has now joined Psycheceutical as chief science officer, commented: “The Janus particle technology has immense potential to transform the delivery of psychedelic therapies amid today’s mental health crisis. Nearly all forms of research being done on psychedelics are via the digestive tract, which slows uptake, requires higher dosage, and may lead to harmful side effects in the body.

“By leveraging nanoparticle encapsulation, Psycheceutical will overcome these limitations. Psycheceutical aims to provide similar nanoparticle-based solutions to any and all companies doing psychedelic drug development research.”

The second system, NeuroDirect™, enables the direct administration of neuroactive compounds to nerve connections to the brain, bypassing the blood-brain-barrier. 

This enables smaller doses, improved efficacy of the active compound, and immediate response, as well as eliminating potentially toxic effects. This delivery method also removes the hallucinogenic effects of the compounds. 

See also  Psychedelics company launches programme for social change

Removing the psychedelic experience

Psycheceutical says the delivery systems’ ability to eliminate the hallucinogenic effects of psychedelic medicines will facilitate wider medical adoption and use.

NeuroDirect™ technology developer, Dr Aung Din, said: “Having practiced neurology and neuropsychiatry for 30 years and been involved in clinical research to bring numerous drugs through the FDA to market, I am particularly excited about Psycheceutical’s work to deliver potentially harmful psychedelics in a safe way for medical purposes. 

“The ability to avoid the systemic side effects of psychedelic compounds, such as nausea, dizziness, and disorientation, opens up a whole new world to neuro-therapeutics.”

“Combining the patented technologies of the Janus particle solution with the NeuroDirect™ delivery system solves the problem most psychedelic drug development companies are targeting: a safe, effective, take-at-home drug. The stronger the medicine, the more likely the need for on-site medical oversight; this layers in massive costs. NeuroDirect delivery, by eliminating toxicity and hallucinogenic properties, solves that problem,” said Chad Harman, CEO of Psycheceutical.

“The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. These breakthrough technologies that allow psychedelic compounds to be delivered in a safer and more effective way are a revolution for the entire psychedelic industry.”

Zappy Zapolin, Psycheceutical chief visionary officer, said: “My unique experience, access, and understanding of the psychedelic industry gives our company, Psycheceutical, a strategic advantage in targeting and acquiring valuable intellectual property and talent flying under the radar of other players in the space.

“Looking at the industry as it is growing, we are seeing the emergence of a brand-new sector: the psycheceutical industry, which merges the best of psychedelics and the best of pharmaceuticals. Psycheceutical is on a mission to bring safety and efficacy to psychedelic compounds with patented delivery systems designed specifically for this new class of medications.”

See also  New peer-reviewed psychedelics journal to launch in 2023

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Industry

Psychedelic therapy programmes launch to address heartbreak, burnout and more

Published

on

Psychedelic therapy programmes launch to address heartbreak, burnout and more

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges. 

Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.

All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.

See also  Psychedelics for frontline workers, palliative care and eating disorders

The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.

Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.

Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.

“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”

“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.

“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”

Additional Mastermind programmes will be released in the coming months, including: Getting Unstuck, by Dr Elizabeth Lombardo; Beating Burnout, by Dr Shauna Shapiro; and Coping with Cravings, by Dr Jud Brewer

“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.

“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”

Continue Reading

Research

Psilocybin analogue shows positive results in Phase 2 depression study

Published

on

Psilocybin analogue shows positive results in Phase 2 depression study

Cybin has announced positive Phase 2 topline safety and efficacy data for its proprietary deuterated psilocybin analogue – CYB003 – for the treatment of major depressive disorder (MDD).

Results from Cybin’s study have shown that 79% of patients were in remission from depression at six weeks after receiving two doses of CYB003.

CYB003 demonstrated a large improvement in symptoms after one dose and a total of 79% of patients were responsive to the treatment. The compound also demonstrated an excellent safety profile in doses tested, with all reported adverse events mild to moderate and self–limiting.

Additionally, Cybin has stated that the magnitude of improvement was superior compared to approved antidepressants and recently reported data with other psychedelics, stating that the effects translate into an unprecedented effect size.

The company has said that the results compare favorably to pooled data from 232 industry studies of current standard-of-care antidepressants, SSRIs, submitted to the FDA.

The announcement follows Phase 2 interim results in early November 2023, which demonstrated that CYB003 saw a “rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo”.

Cybin CEO, Doug Drysdale, stated: “We are delighted to share that CYB003 achieved the primary efficacy endpoint in this study and showed rapid and statistically significant improvements in depression symptoms after a single dose, with a clear incremental benefit of a second dose, resulting in four out of five patients in remission from their depression at six weeks.

“This is an impressive finding and follows on from the unprecedented interim results we announced earlier this month.”

Drysdale emphasised that the strength of the data will support CYB003 into Phase 3 of the study.

Cybin CMO, Amir Inamdar, added: “The significant reduction in depression symptoms observed in our Phase 2 study is highly gratifying.

“At the three-week primary efficacy endpoint, a single 12mg dose of CYB003 showed a rapid, robust, and highly statistically significant improvement in depression symptoms compared to placebo, with a -14.08 point difference in change from baseline in MADRS. 

“This translated into a very large effect size. Similar significant and robust effects were also seen with a single 16mg dose, which resulted in an improvement in symptoms of depression as measured using the MADRS total score by about 13 points versus placebo. 

“These effects were evident on day one with the 16mg dose and were also highly statistically significant. When data from 12mg and 16mg are pooled, these robust effects are maintained. Further, with two doses, response and remission rates in excess of 75% were observed with CYB003 (12mg). 

“With these findings in hand, we are encouraged by the potential of CYB003 to help those with MDD and look forward to progressing to a multinational, multisite Phase 3 study early next year.”

Cybin is planning on submitting topline data to the FDA with an aim to hold a Phase 2 meeting in Q1 of 2024, with further 12-week durability data from Phase 2 CYB003 expected in Q1, and recruitment for the Phase 3 study anticipated to begin by the end of Q1 2024.

Continue Reading

Markets & Industry

Mychedelica launches to revolutionise psychedelic medicine

Published

on

Mychedelica launches to revolutionise psychedelic medicine

A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field. 

With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.

Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.

CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.

“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

mychedelica provides a comprehensive range of services, including:

Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.

Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.

Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.

With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.

Continue Reading

Trending